Log in


-0.67 (-3.26 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: $19.90
50-Day Range
MA: $13.73
52-Week Range
Now: $19.90
Volume65,148 shs
Average Volume113,564 shs
Market Capitalization$130.15 million
P/E RatioN/A
Dividend YieldN/A
BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Ness Ziona, Israel.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:BVXV



Sales & Book Value

Annual SalesN/A
Book Value($1.27) per share


Net Income$-23,410,000.00


Market Cap$130.15 million
Next Earnings Date6/4/2020 (Estimated)
OptionableNot Optionable

Receive BVXV News and Ratings via Email

Sign-up to receive the latest news and ratings for BVXV and its competitors with MarketBeat's FREE daily newsletter.

BIONDVAX PHARMA/S (NASDAQ:BVXV) Frequently Asked Questions

How has BIONDVAX PHARMA/S's stock been impacted by COVID-19 (Coronavirus)?

BIONDVAX PHARMA/S's stock was trading at $6.5350 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BVXV stock has increased by 204.5% and is now trading at $19.90. View which stocks have been most impacted by Coronavirus.

When is BIONDVAX PHARMA/S's next earnings date?

BIONDVAX PHARMA/S is scheduled to release its next quarterly earnings announcement on Thursday, June 4th 2020. View our earnings forecast for BIONDVAX PHARMA/S.

Has BIONDVAX PHARMA/S been receiving favorable news coverage?

Media headlines about BVXV stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. BIONDVAX PHARMA/S earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutBIONDVAX PHARMA/S.

Who are some of BIONDVAX PHARMA/S's key competitors?

What other stocks do shareholders of BIONDVAX PHARMA/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BIONDVAX PHARMA/S investors own include AbbVie (ABBV), Gilead Sciences (GILD), Pluristem Therapeutics (PSTI), Alibaba Group (BABA), Exelixis (EXEL), Agilent Technologies (A), AVEO Pharmaceuticals (AVEO), BIOLINERX LTD/S (BLRX), NVIDIA (NVDA) and Protalix Biotherapeutics (PLX).

Who are BIONDVAX PHARMA/S's key executives?

BIONDVAX PHARMA/S's management team includes the following people:
  • Dr. Ron Babecoff, Co-Founder, CEO, Pres & Director (Age 57)
  • Mr. Uri Ben-Or CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 49)
  • Dr. Tamar Ben Yedidia, Chief Scientific Officer (Age 55)
  • Dr. Shimon Hassin, Chief Operating Officer
  • Mr. Elad Mark, Head of Site & Process Devel.


(BVXV) raised $10 million in an IPO on Tuesday, May 12th 2015. The company issued 1,400,000 shares at $7.32 per share. Aegis Capital Corp served as the underwriter for the IPO.

What is BIONDVAX PHARMA/S's stock symbol?

BIONDVAX PHARMA/S trades on the NASDAQ under the ticker symbol "BVXV."

Who are BIONDVAX PHARMA/S's major shareholders?

BIONDVAX PHARMA/S's stock is owned by many different retail and institutional investors. Top institutional investors include Ibex Investors LLC (5.47%) and HighTower Advisors LLC (0.29%).

Which institutional investors are selling BIONDVAX PHARMA/S stock?

BVXV stock was sold by a variety of institutional investors in the last quarter, including Ibex Investors LLC.

Which institutional investors are buying BIONDVAX PHARMA/S stock?

BVXV stock was acquired by a variety of institutional investors in the last quarter, including HighTower Advisors LLC.

How do I buy shares of BIONDVAX PHARMA/S?

Shares of BVXV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BIONDVAX PHARMA/S's stock price today?

One share of BVXV stock can currently be purchased for approximately $19.90.

How big of a company is BIONDVAX PHARMA/S?

BIONDVAX PHARMA/S has a market capitalization of $130.15 million. BIONDVAX PHARMA/S employs 14 workers across the globe.

What is BIONDVAX PHARMA/S's official website?

The official website for BIONDVAX PHARMA/S is www.biondvax.com.

How can I contact BIONDVAX PHARMA/S?

BIONDVAX PHARMA/S's mailing address is Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036. The company can be reached via phone at 972-8930-2529 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.